Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Commercialization
Biotech
Outlook lays off 23% of staff as it eyes FDA approval, EU debut
The move, which came after an internal strategic review, is meant to streamline operations and save the company $1.4 million annually.
Darren Incorvaia
Dec 16, 2024 8:25am
Dicerna wants partner to sell nedosiran
Aug 10, 2021 8:00am
Epizyme CEO Bazemore passes the baton for 'next phase of growth'
Aug 9, 2021 10:44am
Leveraging Data and Real-World Evidence to Drive Product Success
May 17, 2021 9:00am
Arrowhead, Takeda's RNAi med cuts scarring in rare liver disease
Apr 28, 2021 2:59pm
Orphan and Rare Disease Products
Apr 26, 2021 1:00pm
